Abstract
Aim Evaluation of the effect of acetyl-l-carnitine (ALCAR) vs. amisulpride measured by total Hamilton Depression Rating Scale score (HAM-D21) in patients with pure dysthymia (DSM IV). Two hundred and four patients were randomised and treated with ALCAR 500 mg b.i.d. or amisulpride 50 mg u.i.d. in a double-blind study, for 12 weeks. Results A solid improvement of HAM-D21 was observed in both treatment groups throughout the study. The results did not disclose statistically significant differences between treatments, although the confidence interval for the non-inferiority of the primary end-point exceeded the pre-established limit of 2 by 0.46 points. According to a non-inferiority margin of 3 (considered acceptable by recent published data) the primary end-point could have been fully satisfied. CDRS, MADRS and CGI, employed to further measure the clinical outcome, reported similar results in both treatment groups. The greater tolerability of ALCAR is of clinical relevance considering the chronicity of dysthymia, which often requires prolonged treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 281-287 |
| Number of pages | 7 |
| Journal | European Neuropsychopharmacology |
| Volume | 16 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - May 2006 |
Fingerprint
Keywords
- Acetyl-l-carnitine-ALCAR
- Amisulpride
- Dysthymia
ASJC Scopus subject areas
- Clinical Neurology
- Psychiatry and Mental health
- Biological Psychiatry
- Neurology
- Pharmacology
- Psychology(all)
Cite this
A double-blind, randomised, controlled clinical trial of acetyl-l-carnitine vs. amisulpride in the treatment of dysthymia. / Zanardi, R.; Smeraldi, E.
In: European Neuropsychopharmacology, Vol. 16, No. 4, 05.2006, p. 281-287.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A double-blind, randomised, controlled clinical trial of acetyl-l-carnitine vs. amisulpride in the treatment of dysthymia
AU - Zanardi, R.
AU - Smeraldi, E.
PY - 2006/5
Y1 - 2006/5
N2 - Aim Evaluation of the effect of acetyl-l-carnitine (ALCAR) vs. amisulpride measured by total Hamilton Depression Rating Scale score (HAM-D21) in patients with pure dysthymia (DSM IV). Two hundred and four patients were randomised and treated with ALCAR 500 mg b.i.d. or amisulpride 50 mg u.i.d. in a double-blind study, for 12 weeks. Results A solid improvement of HAM-D21 was observed in both treatment groups throughout the study. The results did not disclose statistically significant differences between treatments, although the confidence interval for the non-inferiority of the primary end-point exceeded the pre-established limit of 2 by 0.46 points. According to a non-inferiority margin of 3 (considered acceptable by recent published data) the primary end-point could have been fully satisfied. CDRS, MADRS and CGI, employed to further measure the clinical outcome, reported similar results in both treatment groups. The greater tolerability of ALCAR is of clinical relevance considering the chronicity of dysthymia, which often requires prolonged treatment.
AB - Aim Evaluation of the effect of acetyl-l-carnitine (ALCAR) vs. amisulpride measured by total Hamilton Depression Rating Scale score (HAM-D21) in patients with pure dysthymia (DSM IV). Two hundred and four patients were randomised and treated with ALCAR 500 mg b.i.d. or amisulpride 50 mg u.i.d. in a double-blind study, for 12 weeks. Results A solid improvement of HAM-D21 was observed in both treatment groups throughout the study. The results did not disclose statistically significant differences between treatments, although the confidence interval for the non-inferiority of the primary end-point exceeded the pre-established limit of 2 by 0.46 points. According to a non-inferiority margin of 3 (considered acceptable by recent published data) the primary end-point could have been fully satisfied. CDRS, MADRS and CGI, employed to further measure the clinical outcome, reported similar results in both treatment groups. The greater tolerability of ALCAR is of clinical relevance considering the chronicity of dysthymia, which often requires prolonged treatment.
KW - Acetyl-l-carnitine-ALCAR
KW - Amisulpride
KW - Dysthymia
UR - http://www.scopus.com/inward/record.url?scp=33645981224&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645981224&partnerID=8YFLogxK
U2 - 10.1016/j.euroneuro.2005.10.005
DO - 10.1016/j.euroneuro.2005.10.005
M3 - Article
C2 - 16316746
AN - SCOPUS:33645981224
VL - 16
SP - 281
EP - 287
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
SN - 0924-977X
IS - 4
ER -